Skip to main content

Advertisement

SpringerLink
Log in

Daily Low-dose Carboplatin as a Radiation Sensitizer for Newly Diagnosed Malignant Glioma

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Surgical resection followed by local field radiotherapy is currently our most effective approach to treatment for most patients with malignant glioma. Carboplatin chemotherapy has direct cytotoxic effects on glioma cells and acts as a radiation sensitizer to enhance cell killing. Its demonstrated efficacy as a sensitizer in other solid tumors led to this clinical trial of carboplatin as a radiation sensitizer in the treatment of newly diagnosed glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). Fourteen patients (nine GBM and five AA) were treated with daily low-dose carboplatin 25 mg/m2 intravenously within 2 h of their fractionated radiotherapy to a total dose of 600 mg/m2. No significant toxicities attributable to this combined therapy were observed. All patients have progressed, with median time to progression of 16 weeks. Eleven patients have died, with median survival of 38 weeks for the entire cohort. Although this regimen appeared safe, there was no benefit in survival time compared to historical patients treated with radiotherapy. The limitations and future potential for the strategy of radiation sensitization are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wen PY, Fine HA, Black PM, Shrieve DC, Alexander E, Loeffler JS: High-grade astrocytomas. In: Wen PY, Black PM (eds) Neurologic Clinics: Brain Tumors in Adults. W.B. Saunders Company, Philadelphia, 1995, pp 875–900

    Google Scholar 

  2. Perry JR, Louis DN, Cairncross JG: Current treatment of oligodendrogliomas. Arch Neurol 56: 434–436, 1999

    Google Scholar 

  3. Walker MD, Alexander EJ, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norell HA, Owens G, Ransahoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333, 1978

    Google Scholar 

  4. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1993

    Google Scholar 

  5. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Djuric L, Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 10: 1074–1077, 1992

    Google Scholar 

  6. Twelves CJ, Ash CM, Miles DW, Thomas DG, Souhami RL: Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Canc Chemother Pharmacol 12: 297–300, 1988

    Google Scholar 

  7. Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C: Carboplatin and recurrent childhood brain tumors. J Clin Oncol 5: 459–463, 1987

    Google Scholar 

  8. Packer J, Ater J, Allen J, Phillips P, Gery R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86: 747–754, 1997

    Google Scholar 

  9. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malec MK: A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neuro-Oncol 19: 69–74, 1994

    Google Scholar 

  10. Yang L, Double EB, O'Hara JA, Crabtree RA, Eastman A: Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines. Radiat Res 144: 230–236, 1995

    Google Scholar 

  11. Yang LX, Double EB, O'Hara JA, Wang HJ: Carboplatin enhances the production and persistence of radiationinduced DNA single-strand breaks. Radiat Res 143: 302–308, 1995

    Google Scholar 

  12. Yang LX, Double EB, O'Hara JA, Wang HJ: Production of DNA double-strand breaks by interaction between carboplatin and radiation: a potential mechanism for radioprotection. Radiat Res 143: 309–315, 1995

    Google Scholar 

  13. Yang LX, Double EB, Wang HJ: Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 33: 641–646, 1995

    Google Scholar 

  14. Yang LX, Double E, Wang HJ: Irradiation-enhanced binding of carboplatin to DNA. Int J Radiat Oncol Biol Phys 68: 609–614, 1995

    Google Scholar 

  15. Aratani Y, Yoshiga K, Mizuuchi H, Jo A, Tanimoto K, Sakuri K: Antitumor effect of carboplatin combined with radiation on tumors in mice. Anticanc Res 17: 2535–2538, 1977

    Google Scholar 

  16. Corn BW, Hernandez E, Anderson L, Fein DA, Dunton CJ, Heller P: Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: an interim report. Am J Clin Oncol 19: 317–321, 1996

    Google Scholar 

  17. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 43: 29–37, 1997

    Google Scholar 

  18. Lau DH, Ryu JK, Gandara DR, Rosenthal SA: Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. Int J Radiat Oncol Biol Phys 38: 157–161, 1977

    Google Scholar 

  19. Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990

    Google Scholar 

  20. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dise 13: 346–353, 1961

    Google Scholar 

  21. Urtasun R, Band P, Chapman JD, Feldstein ML, Mielre B, Fryer C: Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med 294: 1364–1367, 1976

    Google Scholar 

  22. Aiken R, Leavengood JM, Kim JH, Deck MD, Thaler HT, Posner JB: Metronidazaole in the treatment of metastatic brain tumors. Results of a controlled clinical trial. J Neuro-Oncol 2: 105–111, 1984

    Google Scholar 

  23. Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, 3rd, Black PM, Coleman CN: Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys 40: 65–70, 1988

    Google Scholar 

  24. Eyre HJ, Ohlsen JD, Frank J, LoBuglio AF, McCracken JD, Weatherall TJ, Mansfield CM: Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment of metastatic cancer to brain. A Southwest Oncology Group Study. J Neuro-Oncol 2: 325–330, 1984

    Google Scholar 

  25. Gutin PH, Wara WM, Phillips TL, Wilson CB: Hypoxic cell radiosensitizers in the treatment of malignant brain tumors. Neurosurgery 6: 567–576, 1980

    Google Scholar 

  26. Kapp DS, Wagner FC, Lawrence R: Glioblastoma multiforme: treatment by large dose fraction irradiation and metronidazole. Int J Radiat Oncol Biol Phys 8: 351–355, 1982

    Google Scholar 

  27. Huncharek M: Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticanc Res 18: 1935–1939, 1998

    Google Scholar 

  28. Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA: A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45: 127–135, 1999

    Google Scholar 

  29. Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr: A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vncristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys 45: 1109–1115, 1999

    Google Scholar 

  30. Fountzilas G, Karavelis A, Capizzello A, Kalogera-Fountzila A, Karkavelas G, Zamboglou N, Selviaridis P, Foroglou G, Tourkantonis A: Radiation and concomitant weekly administration of paclitaxel in patients with glioblstoma multiforme. A phase II study. J Neuro-Oncol 45: 159–165, 1999

    Google Scholar 

  31. Rosenthal DI, Okani O, Truelson JM, Fatallah-Shaykh H, Vuitch FM, Gazdar AF, Griener J, Landay M, Mendelsohn D, Tourville J, Hamilton L, Orr KY, McWhorter J, Carbone DP: Intensive radiation therapy concurrent with up to 7-week continuous infusion paclitaxel for locally advanced solid tumors: phase I studies. Semin Oncol 24: S2-81-S2-82, 1997

    Google Scholar 

  32. Cvitkovic FB, Haie-Meder C, Papadimitrakopoulou V, Armand JP, Cioloca C, Maugis N, Constans JP: Pilot study of 6 weeks of chemoradiotherapy with 5-FU and hydroxyurea in malignant gliomas. J Neuro-Oncol 15: 9–17, 1993

    Google Scholar 

  33. Prados MD, Larson DA, Lambom K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB: Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 40: 57–63, 1998

    Google Scholar 

  34. Shinoda J, Sakai N, Hara A, Ueda T, Sakai H, Nakatani K: Clinical trial of external beam-radiotherapy combined with daily low-dose cisplatin for supratentorial glioblstoma multiforme - a pilot study. J Neuro-Oncol 35: 73–80, 1997

    Google Scholar 

  35. Poppenborg H, Knupfer MM, Preiss R, Wolff JE, Galla HJ: Cisplatin (CDDP)-induced radiation resistance is not associated with CDDP resistance in 86HG39 and A172 malignant glioma cells. Euro J Canc 35: 1150–1154, 1999

    Google Scholar 

  36. Menei P, Venier MC, Gamelin E, Saint-Andre JP, Hayek G, Jadaud E, Fournier D, Mercier P, Guy G, Benoit JP: Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer 86: 197–199, 1999

    Google Scholar 

  37. Williams JA, Dillehay LE, Tabassi K, Sipos E, Fahlman C, Brem H: Implantable biodegradable polymers for IudR radiosensitization of experimental human malignant glioma. J Neuro-Oncol 32: 181–192, 1997

    Google Scholar 

  38. Yuan X, Tabassi K, Williams JA: Implantable polymers for tirapazamine treatment of experimental intracranial malignant glioma. Radiat Oncol Invest 7: 218–230, 1999

    Google Scholar 

  39. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, Fisher B: Single-arm open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastome multiforme. J Clin Oncol 18: 1254–1259, 2000

    Google Scholar 

  40. Sessler JL, Miller RA: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59: 733–739, 2000

    Google Scholar 

  41. Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M: Phases IB and II multidose trial of gadolinium texaphyrin, a radiosensitizer detectable at MR imaging: preliminary results in brain metastases. Radiolog 212: 755–759, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Stanford University, Stanford, California, USA

    Kendra Peterson

  2. Department of Neurosurgery, Stanford University, Stanford, California, USA

    Griffith Harsh IV & Paul G. Fisher

  3. Department of Radiation Oncology, Stanford University, Stanford, California, USA

    John Adler & Quyhn Le

Authors
  1. Kendra Peterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Griffith Harsh IV
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul G. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Quyhn Le
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peterson, K., Harsh, G., Fisher, P.G. et al. Daily Low-dose Carboplatin as a Radiation Sensitizer for Newly Diagnosed Malignant Glioma. J Neurooncol 53, 27–32 (2001). https://doi.org/10.1023/A:1011891209900

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011891209900

Search

Navigation